Method for inhibiting renal hypofunction in non-human animal

Patent metadata

Field	Value
Publication number	US-11452761-B2
Application number	US-201916239806-A
Country	US
Kind code	B2
Filing date	Jan 4, 2019
Priority date	Jul 4, 2016
Publication date	Sep 27, 2022
Grant date	Sep 27, 2022

Abstract

A method for inhibiting renal hypofunction in a non-human animal includes administering cat-derived erythropoietin to the non-human animal. The non-human animal may have renal hypofunction. The non-human animal may have chronic kidney disease and the renal hypofunction may be caused by the chronic kidney disease. The cat-derived erythropoietin may be administered repeatedly at a time interval of 7 to 30 days.

First claim

What is claimed is:

1. A method for inhibiting renal hypofunction in a non-human mammal, the method comprising administering cat-derived erythropoietin to the non-human mammal,
wherein the administration of the cat-derived erythropoietin inhibits elevation in creatinine concentration in blood and/or elevation in blood urea nitrogen concentration in the non-human mammal,
wherein the non-human mammal is a non-human mammal having chronic kidney disease without anemia during the administration,
wherein the cat-derived erythropoietin comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, an active mutant of SEQ ID NO: 2, and an active mutant of SEQ ID NO: 3,
wherein the active mutant of SEQ ID NO: 2 is an amino acid sequence having 97% or more amino acid identity to SEQ ID NO: 2 and is derived from SEQ ID NO: 2 by addition, deletion, and/or substitution of one or more amino acids, and exhibits at least 60% of erythropoietin activity of the polypeptide consisting of SEQ ID NO: 2,
wherein the active mutant of SEQ ID NO: 3 is an amino acid sequence having 97% or more amino acid identity to SEQ ID NO: 3 and is derived from SEQ ID NO: 3 by addition, deletion, and/or substitution of one or more amino acids, and exhibits at least 60% of erythropoietin activity of the polypeptide consisting of SEQ ID NO: 3,
wherein the cat-derived erythropoietin is chemically modified with polyethylene glycol (PEG),
wherein the chronic kidney disease is classified into chronic kidney disease stage I or stage II defined by the International Renal Interest Society at least at the start of the administration,
wherein a weight-average molecular weight of the PEG is 5 to 40 kDa, and
wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 7 or more days.

2. The method according to claim 1 , wherein the non-human mammal has the chronic kidney disease and the renal hypofunction is caused by the chronic kidney disease.

3. The method according to claim 1 , wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 7 to 30 days.

4. The method according to claim 3 , wherein a dose of the erythropoietin for each administration is 3 to 400 μg/kg body weight.

5. The method according to claim 1 , wherein the non-human mammal has a creatinine concentration in blood of 2.7 mg/dL or lower at least at the start of the administration.

6. The method according to claim 1 , further comprising at least one selected from the group consisting of:
administering an iron supplement to the non-human mammal;
administering intravenous fluids to the non-human mammal;
subjecting the non-human mammal to dialysis;
subjecting the non-human mammal to diet therapy;
administering an antihypertensive agent to the non-human mammal;
administering an adsorbent to the non-human mammal;
administering vitamin to the non-human mammal; and
administering a diuretic to the non-human mammal.

7. The method according to claim 1 , wherein the cat-derived erythropoietin comprises the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 3.

8. The method according to claim 1 , wherein the active mutant of SEQ ID NO: 2 is derived from SEQ ID NO: 2 by addition, deletion, and/or substitution of 1 or 2 amino acids, and the active mutant of SEQ ID NO: 3 is derived from SEQ ID NO: 3 by addition, deletion, and/or substitution of 1 or 2 amino acids.

9. The method according to claim 1 , wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 8 or more days.

10. A method for inhibiting renal hypofunction in a non-human mammal, the method comprising administering cat-derived erythropoietin to the non-human mammal,
wherein the administration of the cat-derived erythropoietin inhibits elevation in creatinine concentration in blood and/or elevation in blood urea nitrogen concentration in the non-human mammal,
wherein the non-human mammal is a non-human mammal having chronic kidney disease without anemia during the administration,
wherein the cat-derived erythropoietin comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, an active mutant of SEQ ID NO: 2 derived from SEQ ID NO: 2 by addition, deletion, and/or substitution of a total 1 to 5 amino acids, and an active mutant of SEQ ID NO: 3 derived from SEQ ID NO: 3 by addition, deletion, and/or substitution of a total 1 to 4 amino acids,
wherein the cat-derived erythropoietin is chemically modified with polyethylene glycol (PEG),
wherein the chronic kidney disease is classified into chronic kidney disease stage I or stage II defined by the International Renal Interest Society at least at the start of the administration,
wherein a weight-average molecular weight of the PEG is 5 to 40 kDa, and
wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 7 or more days.

11. The method according to claim 10 , wherein the active mutant of SEQ ID NO: 2 is derived from SEQ ID NO: 2 by addition, deletion, and/or substitution of 1 or 2 amino acids, and the active mutant of SEQ ID NO: 3 is derived from SEQ ID NO: 3 by addition, deletion, and/or substitution of 1 or 2 amino acids.

12. The method according to claim 10 , wherein the cat-derived erythropoietin comprises the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 3.

13. The method according to claim 10 , wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 8 or more days.

Assignees

• Kaneka Corp

Inventors

• Sakamoto Hirokazu
• Suzuki Hiroetsu
• Katayama Kentaro
• Tochigi Yuki

Classifications

• A61P13/12

  of the kidneys · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title